68837-96-7

Upstream product

• 80866-88-2 (3-methoxy-4-nitrophenyl)methanol 
• 80410-57-7 3-methoxy-4-nitrobenzaldehyde 

Downstream Products

• 895636-32-5 {2-(methyloxy)-4-[(methylsulfonyl)methyl]phenyl}amine 
• 457099-66-0 1-(3-methoxy-4-nitrophenyl)-N,N-dimethylmethanamine 
• 1453199-38-6 N₁-(5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-yl)-4-[(dimethylamino)methyl]-6-methoxybenzene-1,3-diamine 
• 1453199-39-7 N-{5-[5-chloro-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-ylamino]-2-[(dimethylamino)methyl]-4-methoxyphenyl}acrylamide 
• 1453199-37-5 5-chloro-N-{4-[(dimethylamino)methyl]-2-methoxy-5-nitrophenyl}-4-(imidazo[1,2-a]pyridin-3-yl)pyrimidin-2-amine 
• 1453199-36-4 4-[(dimethylamino)methyl]-2-methoxy-5-nitroaniline 
• 927672-81-9 4-[(dimethylamino)methyl]-2-methoxyaniline 
• 1380306-31-9 diethyl (4-{[4-({6-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-(methylcarbamoyl)pyridin-3-yl}amino)-5-(trifluoromethyl)pyridin-2-yl]amino}-3-methoxybenzyl)phosphonate 
• 1380302-86-2 sodium ethyl (4-{[4-({7-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate 
• 1257996-05-6 diethyl (4-{[4-({7-[1-(3-hydroxypropyl)-1H-pyrazol-4-yl]-2-methyl-3-oxo-2,3-dihydro-1H-isoindol-4-yl}amino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate 
• 1257996-52-3 diethyl (4-amino-3-methoxybenzyl)phosphonate 
• 1257996-58-9 diethyl (4-{[4-chloro-5-(trifluoromethyl)pyrimidin-2-yl]amino}-3-methoxybenzyl)phosphonate 
• 1257996-99-8 diethyl (3-methoxy-4-nitrobenzyl)phosphonate 

Relevant academic research and scientific papers

MACROCYCLIC KINASE INHIBITORS

Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial.

2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER

Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.